Health Canada consultation on proposed vaping products promotion regulations
https://policybase.cma.ca/link/policy14128

POLICY TYPE
Response to consultation

DATE
2020-01-20

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Health Canada consultation on vaping products labelling and packaging regulations
https://policybase.cma.ca/link/policy14124

POLICY TYPE: Response to consultation
DATE: 2019-09-05
TOPICS: Health care and patient safety
Population health, health equity, public health

Documents
Health Canada consultation on potential market for cannabis health products that would not require practitioner oversight
https://policybase.cma.ca/link/policy14125

POLICY TYPE: Response to consultation
DATE: 2019-09-03
TOPICS: Health care and patient safety, Population health, health equity, public health

Documents
Health Canada consultation on the impact of vaping products advertising on youth and non-users of tobacco products
https://policybase.cma.ca/link/policy14022

POLICY TYPE: Response to consultation
DATE: 2019-03-22
TOPICS: Health care and patient safety
Population health, health equity, public health

Documents
Health Canada’s consultation on new health-related labelling for tobacco products
https://policybase.cma.ca/link/policy13939

POLICY TYPE
Response to consultation

DATE
2018-12-14

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Implementation of National Pharmacare
https://policybase.cma.ca/link/policy13933

POLICY TYPE
Response to consultation

DATE
2018-10-02

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA submission:
IMPLEMENTATION OF NATIONAL PHARMACARE

Submission to the Advisory Council
Teammath 2018
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
https://policybase.cma.ca/link/policy13930

POLICY TYPE: Response to consultation
DATE: 2018-09-06
TOPICS: Health care and patient safety, Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on proposed front-of-package labelling
https://policybase.cma.ca/link/policy13882

POLICY TYPE
Response to consultation

DATE
2018-04-23

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Dear [Name],

The Canadian Medical Association (CMA) welcomes the opportunity to provide comments on the Consultation on the Renewal of Federal Tobacco Control Strategy. CMA was pleased to have the opportunity to participate in the consultation and contribute to the development of a comprehensive and evidence-based strategy to address tobacco use.

The CMA supports the goals of the proposed strategy, particularly in the areas of tobacco control, supporting public health efforts, and promoting healthy lifestyles. The proposed strategy aligns with the CMA’s recommendations for a comprehensive approach to tobacco control, including funding for public health initiatives, research, and evaluation.

CMA encourages the federal government to continue to support tobacco control initiatives and to implement evidence-based policies to reduce tobacco use. We appreciate the opportunity to provide comments on the Consultation on the Renewal of Federal Tobacco Control Strategy and look forward to seeing the final strategy.

Yours sincerely,

[Signed]

[Name]
[Position]

Canadian Medical Association

[Date]
Consultation on the renewal of Federal Tobacco Control Strategy

https://policybase.cma.ca/link/policy13804

POLICY TYPE  Response to consultation

DATE  2017-04-05

TOPICS  Health care and patient safety

Pharmaceuticals, prescribing, cannabis, drugs

Documents

A J, 2017

Consultation on the renewal of Federal Tobacco Control Strategy

On behalf of the Canadian Medical Association (CMA), I am writing in your regard the consultation on renewal of the Federal Tobacco Control Strategy (FTCS), and on the Submission of the Canadian Medical Association’s (CMA) “Tobacco Control in Canada: We must protect our children, strengthen the FTCS.”

As the First Nation’s Canadian Healthy Survey reports, 31.2% of the population aged 14 and older have smoked tobacco in the previous year. This high prevalence of smoking among adults highlights the need to ensure that the measures are effective in reducing smoking rates.

We support the Senate’s Senate goal of less than 5% of adults using tobacco by 2030. It must be understood that specific communities, such as indigenous populations, will require tailored approaches.

The CMA supports the Senate’s recommendation to increase the excise tax on all tobacco products, and to ensure that the measures are effective in reducing smoking rates.

As the Senate’s report highlights, a continued reduction in smoking rates, tobacco use among youth, and the associated health care costs, will require a comprehensive approach.

The CMA believes that effective, low-cost interventions are critical in achieving the desired reductions in smoking rates. Tobacco use among youth is a priority, and should continue to be supported by a sustained, well-funded tobacco strategy and strong engagement and support from Health Canada, including a comprehensive approach to reduce smoking rates.

We look forward to the opportunity to discuss these recommendations with you further.

Sincerely,

Dr. J. A.

The Canadian Medical Association (CMA)

CMA Policybase - Canadian Medical Association
Front-of-package labelling consultation
https://policybase.cma.ca/link/policy13800

POLICY TYPE
Response to consultation

DATE
2016-10-31

TOPICS
Health care and patient safety

Documents
Regulation of Self-Care Products in Canada
https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE  2016-10-31
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
   Health care and patient safety

Documents
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE Response to consultation
DATE 2016-08-12
TOPICS Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE  Response to consultation
DATE  2016-01-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents